FISHERS, Ind., Dec. 19, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce that on December 16, 2011, the Company received a nuclear pharmacy license from the Indiana Board of Pharmacy for the Company's Crown Point, Indiana manufacturing facility.
The Indiana Board of Pharmacy license completes the requirements necessary to amend its NRC license to allow Positron to manufacture and distribute radiochemicals and radiopharmaceuticals throughout the United States. The Company will begin to produce Indium 111 Oxyquinoline for customer evaluation and commercial sale.
"We are pleased to receive this approval as it will allow our Crown Point facility to become fully licensed and operational as a radiochemical manufacturing facility," said Scott Stiffler, Positron's Vice President of Pharmaceuticals. "The Crown Point facility provides an ideal site for the manufacturing and development of radiopharmaceuticals and radiochemicals. The revenue generated from our Indium Oxyquinoline sales will allow Positron to expand its current product offerings. I'm pleased with the team's efforts and execution at Crown Point of this significant milestone."
About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine. Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
SOURCE Positron Corporation